Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06679465
PHASE4
Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response
Sponsor: University of Saskatchewan
View on ClinicalTrials.gov
Summary
Evaluate single dose (2 x 2.5mcg/puff; total dose 5mcg) effect of tiotropium administered 30 minutes prior to allergen challenge on allergen-induced EAR assessed as the maximal % fall in FEV1 after allergen inhalation compared to that of single dose (two puffs) matched placebo administered 30 minutes prior to allergen challenge.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2025-01-01
Completion Date
2027-01
Last Updated
2024-11-07
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tiotropium (Spiriva®)
2 puffs tiotropium prior to allergen challenge
DRUG
Placebo
2 puffs placebo
Locations (1)
University of Saskatchewan
Saskatoon, Saskatchewan, Canada